Calidi Biotherapeutics, Inc. (CLDI)
CLDI Stock Price Chart
Explore Calidi Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CLDI price movements and trends.
CLDI Company Profile
Discover essential business fundamentals and corporate details for Calidi Biotherapeutics, Inc. (CLDI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Nov 2021
Employees
28.00
Website
https://calidibio.comCEO
Eric E. Poma
Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
CLDI Financial Timeline
Browse a chronological timeline of Calidi Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
Earnings released on 8 Aug 2025
EPS came in at -$1.99 falling short of the estimated -$1.92 by -3.65%.
Stock split effective on 5 Aug 2025
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2025
EPS came in at -$2.16 falling short of the estimated -$0.15 by -1.34K%.
Earnings released on 4 Apr 2025
EPS came in at -$0.51 falling short of the estimated -$0.37 by -37.84%, while revenue for the quarter reached $1.50M .
Earnings released on 12 Nov 2024
EPS came in at -$7.80 falling short of the estimated -$0.85 by -817.65%.
Earnings released on 13 Aug 2024
EPS came in at -$16.81 falling short of the estimated -$1.43 by -1.08K%.
Earnings released on 13 Aug 2024
EPS came in at -$24.48 .
Stock split effective on 15 Jul 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Mar 2024
EPS came in at -$0.48 falling short of the estimated -$0.20 by -140.00%.
Earnings released on 14 Nov 2023
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%.
Earnings released on 29 Jun 2023
EPS came in at -$152.47 .
Earnings released on 31 Mar 2023
EPS came in at -$78.82 .
Earnings released on 31 Dec 2022
EPS came in at -$94.60 .
Earnings released on 29 Sept 2022
EPS came in at -$24.35 .
Earnings released on 29 Jun 2022
EPS came in at $17.44 .
Earnings released on 30 Mar 2022
EPS came in at $6.13 .
Earnings released on 30 Dec 2021
EPS came in at -$14.62 .
Earnings released on 29 Sept 2021
EPS came in at -$3.45 .
Earnings released on 30 Jun 2021
EPS came in at -$0.04 .
CLDI Stock Performance
Access detailed CLDI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.